Literature DB >> 15542441

Stromal cell-derived factor-1 (SDF-1)\CXCR4 couple plays multiple roles on haematopoietic progenitors at the border between the old cytokine and new chemokine worlds: survival, cell cycling and trafficking.

Jean-Jacques Lataillade1, Jorge Domenech, Marie-Caroline Le Bousse-Kerdilès.   

Abstract

Generation of haematopoietic cells is regulated by cellular and humoral interactions in which stromal cells, adhesion molecules, cytokines and chemokines play a crucial role. Among the chemokines, SDF-1 and its CXCR4 receptor have been reported to be key players in the nesting of haematopoietic progenitors within the bone marrow. Disruption of the SDF-1\CXCR4 axis results in cell mobilization and may participate in leukaemia extramedullary infiltration. In this review we will discuss the manifold roles of the SDF-1 chemokine and of its receptor in haematopoiesis regulation. By recruiting quiescent progenitors, by participating in their survival\cycling and by sensitizing them to further cytokine synergistic action, SDF-1 likely contributes to haematopoiesis homeostasis under physiological conditions and in stress situations. The complexity of the SDF-1\CXCR4 interactions in the regulation of haematopoiesis illustrates a dynamic and sequential cross-talk between chemokine and cytokine\growth factor worlds. Because of their pleiotropic effects on haematopoietic progenitor trafficking, survival and proliferation, the SDF-1\CXCR4 couple could be considered as promising molecules for improvement of cell-based therapy protocols in haematopoietic transplantation.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15542441

Source DB:  PubMed          Journal:  Eur Cytokine Netw        ISSN: 1148-5493            Impact factor:   2.737


  27 in total

Review 1.  CXCL12 in control of neuroinflammation.

Authors:  Miljana Momcilović; Marija Mostarica-Stojković; Djordje Miljković
Journal:  Immunol Res       Date:  2012-04       Impact factor: 2.829

2.  An integrated approach for the mechanisms responsible for atherosclerotic plaque regression.

Authors:  Andrew A Francis; Grant N Pierce
Journal:  Exp Clin Cardiol       Date:  2011

3.  Characterization of the CXCR4 signaling in pancreatic cancer cells.

Authors:  Daniel D Billadeau; Subrha Chatterjee; Patricia Bramati; Raghavakaimal Sreekumar; Vijay Shah; Karen Hedin; Raul Urrutia
Journal:  Int J Gastrointest Cancer       Date:  2006

Review 4.  Multiple roles of chemokine CXCL12 in the central nervous system: a migration from immunology to neurobiology.

Authors:  Meizhang Li; Richard M Ransohoff
Journal:  Prog Neurobiol       Date:  2007-11-26       Impact factor: 11.685

5.  Human β-defensin-3 structure motifs that are important in CXCR4 antagonism.

Authors:  Zhimin Feng; George R Dubyak; Xun Jia; Jacek T Lubkowski; Aaron Weinberg
Journal:  FEBS J       Date:  2013-06-07       Impact factor: 5.542

6.  Cell surface nucleolin interacts with CXCR4 receptor via the 212 c-terminal portion.

Authors:  Hongxin Niu; Xiangshan Yang; Zhongfa Xu; Tong Du; Ruogu Wang
Journal:  Tumour Biol       Date:  2014-10-19

7.  Regulation of granulosa and theca cell transcriptomes during ovarian antral follicle development.

Authors:  Michael K Skinner; Michelle Schmidt; Marina I Savenkova; Ingrid Sadler-Riggleman; Eric E Nilsson
Journal:  Mol Reprod Dev       Date:  2008-09       Impact factor: 2.609

8.  Stem/Progenitor cells, atherosclerosis and cardiovascular regeneration.

Authors:  Olena Dotsenko
Journal:  Open Cardiovasc Med J       Date:  2010-02-23

9.  Phosphorylation of collapsin response mediator protein 2 on Tyr-479 regulates CXCL12-induced T lymphocyte migration.

Authors:  Michel Varrin-Doyer; Peggy Vincent; Sylvie Cavagna; Nathalie Auvergnon; Nelly Noraz; Véronique Rogemond; Jérôme Honnorat; Mahnaz Moradi-Améli; Pascale Giraudon
Journal:  J Biol Chem       Date:  2009-03-10       Impact factor: 5.157

10.  Airway smooth muscle chemokine receptor expression and function in asthma.

Authors:  R Saunders; A Sutcliffe; D Kaur; S Siddiqui; F Hollins; A Wardlaw; P Bradding; C Brightling
Journal:  Clin Exp Allergy       Date:  2009-09-07       Impact factor: 5.018

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.